- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 08.09. | Apnimed, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 08.09. | Apnimed, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.09. | Apnimed, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Apnimed, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| APNIMED Aktie jetzt für 0€ handeln | |||||
| 08.09. | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 365 | GlobeNewswire (Europe) | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| 04.09. | Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 25.08. | Apnimed rises on Street initiations following IPO | 1 | Seeking Alpha | ||
| 25.08. | Cantor Fitzgerald initiates Apnimed stock with overweight rating | 1 | Investing.com | ||
| 25.08. | BofA initiates Apnimed stock with buy rating on sleep apnea drug | 1 | Investing.com | ||
| 03.08. | Apnimed erzielt 220,8 Mio. US-Dollar bei NASDAQ-Börsengang | 1 | Investing.com Deutsch | ||
| 03.08. | Apnimed closes $220.8 million IPO on Nasdaq | 1 | Investing.com | ||
| 03.08. | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 418 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| 03.08. | Apnimed, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | Apnimed's IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug | 5 | MedCity News | ||
| 31.07. | Apnimed, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 31.07. | Sleep drug developer Apnimed rises on trading debut | 1 | Seeking Alpha | ||
| 31.07. | Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs | 32 | BioPharma Dive | ||
| 31.07. | Sleep apnea pill developer Apnimed prices upsized IPO at $16, the high end of the range | 9 | Renaissance Capital | ||
| 31.07. | Apnimed IPO raises $192m, as three other biotechs set terms | 1 | pharmaphorum |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| VIATRIS | 15,400 | -1,52 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| INCYTE | 102,25 | -0,20 % | Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals und Incyte melden FDA-Zulassung für Atebrioz (Zilurgisertib) für erwachsene und pädiatrische Patienten mit Fibrodysplasia ossificans progressiva | - Einmal täglich oral verabreichter ALK2-Hemmer erhält Zulassung zur Reduzierung des Volumens der gesamten neuen heterotopischen Verknöcherung bei Patienten mit FOP im Alter von über 12 Jahren ... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 19,700 | -1,50 % | Assembly Biosciences: Jetzt startet der Herpes-Countdown | ||
| BIONANO GENOMICS | 1,490 | +0,68 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 38,650 | -0,21 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,891 | +8,00 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ALTIMMUNE | 2,440 | +0,41 % | Altimmune forciert mit Pemvidutid Expansion bei Lebererkrankungen | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| ORION | 81,05 | -0,12 % | Orion Oyj: Orion Corporation completed share acquisitions | ||
| WAVE LIFE SCIENCES | 3,545 | +5,35 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD | Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing)... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,570 | -0,58 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine | Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 2,180 | 0,00 % | Eledon Pharmaceuticals, Inc.: Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society | Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 3,786 | -2,82 % | Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating | ||
| MEDICINOVA | 1,800 | +1,12 % | MediciNova, Inc.: MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen |
APNIMED INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,09 % bei einem Aktienkurs von 21,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APNIMED INC finden Sie auf Wallstreet Online.